These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 33190022)

  • 1. Characterisation of a novel thrombomodulin c.1487delC,p.(Pro496Argfs*10) variant and evaluation of therapeutic strategies to manage the rare bleeding phenotype.
    Morrow GB; Beavis J; Harper S; Bignell P; Laffan MA; Curry N
    Thromb Res; 2021 Jan; 197():100-108. PubMed ID: 33190022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new pedigree with thrombomodulin-associated coagulopathy in which delayed fibrinolysis is partially attenuated by co-inherited TAFI deficiency.
    Westbury SK; Whyte CS; Stephens J; Downes K; Turro E; Claesen K; Mertens JC; Hendriks D; Latif AL; Leishman EJ; ; Mutch NJ; Tait RC; Mumford AD
    J Thromb Haemost; 2020 Sep; 18(9):2209-2214. PubMed ID: 32634856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
    Mosnier LO
    J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
    Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
    Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. VhH anti-thrombomodulin clone 1 inhibits TAFI activation and enhances fibrinolysis in human whole blood under flow.
    van Moorsel MVA; Poolen GC; Koekman CA; Verhoef S; de Maat S; Barendrecht A; van Kleef ND; Meijers JCM; Schiffelers RM; Maas C; Urbanus RT
    J Thromb Haemost; 2022 May; 20(5):1213-1222. PubMed ID: 35170225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of thrombomodulin/thrombin activatable fibrinolysis inhibitor function in plasma using tissue-type plasminogen activator-induced plasma clot lysis time.
    Urano T; Sano Y; Suzuki Y; Okada M; Sano H; Honkura N; Morooka N; Doi M; Suzuki Y
    Res Pract Thromb Haemost; 2024 May; 8(4):102463. PubMed ID: 39026660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble thrombomodulin partially corrects the premature lysis defect in FVIII-deficient plasma by stimulating the activation of thrombin activatable fibrinolysis inhibitor.
    Foley JH; Nesheim ME
    J Thromb Haemost; 2009 Mar; 7(3):453-9. PubMed ID: 19087221
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered fibrinolysis in autosomal dominant thrombomodulin-associated coagulopathy.
    Burley K; Whyte CS; Westbury SK; Walker M; Stirrups KE; Turro E; ; Chapman OG; Reilly-Stitt C; Mutch NJ; Mumford AD
    Blood; 2016 Oct; 128(14):1879-1883. PubMed ID: 27436851
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thrombomodulin suppresses invasiveness of HT1080 tumor cells by reducing plasminogen activation on the cell surface through activation of thrombin-activatable fibrinolysis inhibitor.
    Higuchi T; Nakamura T; Kakutani H; Ishii H
    Biol Pharm Bull; 2009 Feb; 32(2):179-85. PubMed ID: 19182372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Both cellular and soluble forms of thrombomodulin inhibit fibrinolysis by potentiating the activation of thrombin-activable fibrinolysis inhibitor.
    Bajzar L; Nesheim M; Morser J; Tracy PB
    J Biol Chem; 1998 Jan; 273(5):2792-8. PubMed ID: 9446587
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
    Bajzar L; Nesheim ME; Tracy PB
    Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The paradoxical antifibrinolytic effect of dabigatran and argatroban in the presence of soluble thrombomodulin is unrelated to protein C-dependent increase of thrombin generation.
    Incampo F; Carrieri C; Semeraro N; Colucci M
    Thromb Res; 2014 Nov; 134(5):1110-6. PubMed ID: 25193406
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis.
    Dai L; Mitchell M; Savidge G; Alhaq A
    J Thromb Haemost; 2004 Dec; 2(12):2200-4. PubMed ID: 15613027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma carboxypeptidase U (CPU, CPB2, TAFIa) generation during in vitro clot lysis and its interplay between coagulation and fibrinolysis.
    Leenaerts D; Aernouts J; Van Der Veken P; Sim Y; Lambeir AM; Hendriks D
    Thromb Haemost; 2017 Jul; 117(8):1498-1508. PubMed ID: 28692110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombin-activatable fibrinolysis inhibitor antigen and TAFI activity in patients with APC resistance caused by factor V Leiden mutation.
    Antovic JP; Blombäck M
    Thromb Res; 2002 Apr; 106(1):59-62. PubMed ID: 12165290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombin activatable fibrinolysis inhibitor pathway alterations correlate with bleeding phenotype in patients with severe hemophilia A.
    Semeraro F; Mancuso ME; Ammollo CT; Dirienzo L; Vitulli A; Santagostino E; Tripodi A; Colucci M
    J Thromb Haemost; 2020 Feb; 18(2):381-389. PubMed ID: 31571361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
    Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY
    Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
    Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
    J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated platelet-based inhibition of fibrinolysis via thrombin-activatable fibrinolysis inhibitor activation system.
    Suzuki Y; Sano H; Mochizuki L; Honkura N; Urano T
    Blood Adv; 2020 Nov; 4(21):5501-5511. PubMed ID: 33166409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined effect of a direct oral anticoagulant edoxaban and an inhibitor of activated thrombin-activatable fibrinolysis inhibitor on clot lysis.
    Morishima Y; Kamisato C; Honda Y
    J Thromb Thrombolysis; 2020 Jan; 49(1):94-99. PubMed ID: 31396790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.